TA125 Psoriatic arthritis (moderate to severe) - adalimumab: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA125 – Adalimumab for the treatment of psoriatic arthritis The Institute would welcome feedback from users to inform the development of future templates.